Additional file 5 of Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
收藏数据链接：
官方服务：
资源简介：
Additional file 5: Table S4. CTNNB1 mutations detected in pembrolizumab-treated patients.
创建时间：
2022-01-06
